{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:26:24Z","timestamp":1773271584738,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T00:00:00Z","timestamp":1505347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T00:00:00Z","timestamp":1505347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1038\/gt.2017.67","type":"journal-article","created":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T10:24:04Z","timestamp":1505384644000},"page":"742-748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene"],"prefix":"10.1038","volume":"24","author":[{"given":"J M","family":"Staber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M J","family":"Pollpeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C-G","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Burrascano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A L","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P L","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D T","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W C","family":"Raschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P B","family":"McCray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,14]]},"reference":[{"key":"BFgt201767_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1056\/NEJM199401063300108","volume":"330","author":"LW Hoyer","year":"1994","unstructured":"Hoyer LW . Hemophilia A. N Engl J Med 1994; 330: 38\u201347.","journal-title":"N Engl J Med"},{"key":"BFgt201767_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF01714977","volume":"62","author":"FR Rosendaal","year":"1991","unstructured":"Rosendaal FR, Smit C, Briet E . Hemophilia treatment in historical perspective: a review of medical and social developments. Ann Hematol 1991; 62: 5\u201315.","journal-title":"Ann Hematol"},{"key":"BFgt201767_CR3","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1089\/10430349950017095","volume":"10","author":"RJ Kaufman","year":"1999","unstructured":"Kaufman RJ . Advances toward gene therapy for hemophilia at the millennium. Hum Gene Ther 1999; 10: 2091\u20132107.","journal-title":"Hum Gene Ther"},{"key":"BFgt201767_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1521-2254(200101\/02)3:1<3::AID-JGM167>3.0.CO;2-H","volume":"3","author":"MK Chuah","year":"2001","unstructured":"Chuah MK, Collen D, VandenDriessche T . Gene therapy for hemophilia. J Gene Med 2001; 3: 3\u201320.","journal-title":"J Gene Med"},{"key":"BFgt201767_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1365-2141.1995.tb05575.x","volume":"90","author":"LW Hoyer","year":"1995","unstructured":"Hoyer LW . Why do so many haemophilia A patients develop an inhibitor? Br J Haematol 1995; 90: 498\u2013501.","journal-title":"Br J Haematol"},{"key":"BFgt201767_CR6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1055\/s-0037-1614450","volume":"81","author":"J Qian","year":"1999","unstructured":"Qian J, Borovok M, Bi L, Kazazian Jr HH, Hoyer LW . Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 1999; 81: 240\u2013244.","journal-title":"Thromb Haemost"},{"key":"BFgt201767_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1055\/s-2000-9819","volume":"26","author":"SS Fakharzadeh","year":"2000","unstructured":"Fakharzadeh SS, Kazazian HH Jr . Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost 2000; 26: 167\u2013171.","journal-title":"Semin Thromb Hemost"},{"key":"BFgt201767_CR8","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood.V95.9.2799.009k23_2799_2805","volume":"95","author":"SS Fakharzadeh","year":"2000","unstructured":"Fakharzadeh SS, Zhang Y, Sarkar R, Kazazian HH Jr . Correction of the coagulation defect in hemophilia A mice through factor VIII expression in skin. Blood 2000; 95: 2799\u20132805.","journal-title":"Blood"},{"key":"BFgt201767_CR9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1046\/j.1538-7836.2003.00096.x","volume":"1","author":"R Sarkar","year":"2003","unstructured":"Sarkar R, Xiao W, Kazazian HH Jr. . A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype. J Thromb Haemost 2003; 1: 220\u2013226.","journal-title":"J Thromb Haemost"},{"key":"BFgt201767_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1089\/hum.2006.17.427","volume":"17","author":"R Sarkar","year":"2006","unstructured":"Sarkar R, Mucci M, Addya S, Tetreault R, Bellinger DA, Nichols TC et al. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. Hum Gene Ther 2006; 17: 427\u2013439.","journal-title":"Hum Gene Ther"},{"key":"BFgt201767_CR11","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1525-0016(03)00073-X","volume":"7","author":"NA Kootstra","year":"2003","unstructured":"Kootstra NA, Matsumura R, Verma IM . Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Mol Ther 2003; 7: 623\u2013631.","journal-title":"Mol Ther"},{"key":"BFgt201767_CR12","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1182\/blood.V88.10.3846.bloodjournal88103846","volume":"88","author":"S Connelly","year":"1996","unstructured":"Connelly S, Mount J, Mauser A, Gardner JM, Kaleko M, McClelland A et al. Complete short-term correction of canine hemophilia a by in vivo gene therapy. Blood 1996; 88: 3846\u20133853.","journal-title":"Blood"},{"key":"BFgt201767_CR13","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood.V91.9.3273","volume":"9","author":"S Connelly","year":"1998","unstructured":"Connelly S, Andrews JL, Gallo AM, Kayda DB, Qian J, Hoyer L et al. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 1998; 9: 3273\u20133281.","journal-title":"Blood"},{"key":"BFgt201767_CR14","doi-asserted-by":"publisher","first-page":"13324","DOI":"10.1073\/pnas.96.23.13324","volume":"96","author":"GS Lipshutz","year":"1999","unstructured":"Lipshutz GS, Sarkar R, Flebbe-Rehwaldt L, Kazazian H, Gaensler KM . Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero. Proc Natl Acad Sci USA 1999; 96: 13324\u201313329.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFgt201767_CR15","doi-asserted-by":"publisher","first-page":"10379","DOI":"10.1073\/pnas.96.18.10379","volume":"96","author":"T VandenDriessche","year":"1999","unstructured":"VandenDriessche T, Vanslembrouck V, Goovaerts I, Zwinnen H, Vanderhaeghen ML, Collen D et al. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc Natl Acad Sci USA 1999; 96: 10379\u201310384.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFgt201767_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/01.moh.0000239700.94555.b1","volume":"13","author":"KP Ponder","year":"2006","unstructured":"Ponder KP . Gene therapy for hemophilia. Curr Opin Hematol 2006; 13: 301\u2013307.","journal-title":"Curr Opin Hematol"},{"key":"BFgt201767_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nm0397-306","volume":"3","author":"KJ Fisher","year":"1997","unstructured":"Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med 1997; 3: 306\u2013312.","journal-title":"Nature Med"},{"key":"BFgt201767_CR18","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ymthe.2005.09.007","volume":"12","author":"M Moayeri","year":"2005","unstructured":"Moayeri M, Hawley TS, Hawley RG . Correction of murine hemophilia A by hematopoietic stem cell gene therapy. Mol Ther 2005; 12: 1034\u20131042.","journal-title":"Mol Ther"},{"key":"BFgt201767_CR19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1538-7836.2007.02346.x","volume":"5","author":"Q Shi","year":"2007","unstructured":"Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, Du LM et al. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost 2007; 5: 352\u2013361.","journal-title":"J Thromb Haemost"},{"issue":"suppl 5","key":"BFgt201767_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/hae.13011","volume":"22","author":"HT Spencer","year":"2016","unstructured":"Spencer HT, Riley BE, Doering CB . State of the art: gene therapy of haemophilia. Haemophilia 2016; 22 (suppl 5): 66\u201371.","journal-title":"Haemophilia"},{"key":"BFgt201767_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.blre.2015.03.002","volume":"29","author":"E Lheriteau","year":"2015","unstructured":"Lheriteau E, Davidoff AM, Nathwani AC . Haemophilia gene therapy: progress and challenges. Blood Rev 2015; 29: 321\u2013328.","journal-title":"Blood Rev"},{"key":"BFgt201767_CR22","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood-2004-11-4358","volume":"106","author":"Y Kang","year":"2005","unstructured":"Kang Y, Xie L, Tran DT, Stein CS, Hickey M, Davidson BL et al. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Blood 2005; 106: 1552\u20131558.","journal-title":"Blood"},{"key":"BFgt201767_CR23","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1056\/NEJM200106073442301","volume":"344","author":"DA Roth","year":"2001","unstructured":"Roth DA, Tawa Jr NE, O'Brien JM, Treco DA, Selden RF, Factor VTTSG . Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001; 344: 1735\u20131742.","journal-title":"N Engl J Med"},{"key":"BFgt201767_CR24","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1055\/s-0037-1615881","volume":"82","author":"WW Zhang","year":"1999","unstructured":"Zhang WW, Josephs SF, Zhou J, Fang X, Alemany R, Balague C et al. Development and application of a minimal-adenoviral vector system for gene therapy of hemophilia A. Thromb Haemost 1999; 82: 562\u2013571.","journal-title":"Thromb Haemost"},{"key":"BFgt201767_CR25","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1089\/hum.2006.127","volume":"18","author":"PL Sinn","year":"2007","unstructured":"Sinn PL, Goreham-Voss JD, Arias AC, Hickey MA, Maury W, Chikkanna-Gowda CP et al. Enhanced gene expression conferred by stepwise modification of a non-primate lentiviral vector. Hum Gen Ther 2007; 18: 1244\u20131252.","journal-title":"Hum Gen Ther"},{"key":"BFgt201767_CR26","doi-asserted-by":"publisher","first-page":"14042","DOI":"10.1038\/mtm.2014.42","volume":"1","author":"JM Staber","year":"2014","unstructured":"Staber JM, Pollpeter MJ, Arensdorf A, Sinn PL, Rutkowski DT, McCray PB Jr . piggyBac-mediated phenotypic correction of factor VIII deficiency. Mol Ther Methods Clin Dev 2014; 1: 14042.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"BFgt201767_CR27","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1089\/104303401753153947","volume":"12","author":"M Kumar","year":"2001","unstructured":"Kumar M, Keller B, Makalou N, Sutton RE . Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther 2001; 12: 1893\u20131905.","journal-title":"Hum Gene Ther"},{"key":"BFgt201767_CR28","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1128\/JVI.73.6.4991-5000.1999","volume":"73","author":"JC Johnston","year":"1999","unstructured":"Johnston JC, Gasmi M, Lim LE, Elder JH, Yee J-K, Jolly DJ et al. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J Virol 1999; 73: 4991\u20135000.","journal-title":"J Virol"},{"key":"BFgt201767_CR29","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1182\/blood-2010-05-282707","volume":"117","author":"NJ Ward","year":"2011","unstructured":"Ward NJ, Buckley SM, Waddington SN, Vandendriessche T, Chuah MK, Nathwani AC et al. Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood 2011; 117: 798\u2013807.","journal-title":"Blood"},{"key":"BFgt201767_CR30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1055\/s-0037-1614984","volume":"79","author":"C Cameron","year":"1998","unstructured":"Cameron C, Notley C, Hoyle S, McGlynn L, Hough C, Kamisue S et al. The canine factor VIII cDNA and 5' flanking sequence. Thromb Haemost 1998; 79: 317\u2013322.","journal-title":"Thromb Haemost"},{"key":"BFgt201767_CR31","doi-asserted-by":"publisher","first-page":"18525","DOI":"10.1073\/pnas.0809677105","volume":"105","author":"JD Malhotra","year":"2008","unstructured":"Malhotra JD, Miao H, Zhang K, Wolfson A, Pennathur S, Pipe SW et al. Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. Proc Natl Acad Sci USA 2008; 105: 18525\u201318530.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFgt201767_CR32","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1182\/blood-2003-10-3591","volume":"103","author":"HZ Miao","year":"2004","unstructured":"Miao HZ, Sirachainan N, Palmer L, Kucab P, Cunningham MA, Kaufman RJ et al. Bioengineering of coagulation factor VIII for improved secretion. Blood 2004; 103: 3412\u20133419.","journal-title":"Blood"},{"key":"BFgt201767_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1097-2765(03)00105-9","volume":"11","author":"HP Harding","year":"2003","unstructured":"Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 2003; 11: 619\u2013633.","journal-title":"Mol Cell"},{"issue":"277","key":"BFgt201767_CR34","doi-asserted-by":"publisher","first-page":"277ra28","DOI":"10.1126\/scitranslmed.aaa1405","volume":"7","author":"Alessio Cantore","year":"2015","unstructured":"Cantore A, Ranzani M, Bartholomae CC, Volpin M, Valle PD, Sanvito F et al. Liver-directed lentiviral gene therapy in a dog model of hemophilia B. Sci Transl Med 2015; 7 277ra28.","journal-title":"Science Translational Medicine"},{"key":"BFgt201767_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jbiotec.2016.10.016","volume":"240","author":"A McCarron","year":"2016","unstructured":"McCarron A, Donnelley M, McIntyre C, Parsons D . Challenges of up-scaling lentivirus production and processing. J Biotechnol 2016; 240: 23\u201330.","journal-title":"J Biotechnol"},{"key":"BFgt201767_CR36","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1089\/hum.2006.127","volume":"18","author":"PL Sinn","year":"2007","unstructured":"Sinn PL, Goreham-Voss JD, Arias AC, Hickey MA, Maury W, Chikkanna-Gowda CP et al. Enhanced gene expression conferred by stepwise modification of a nonprimate lentiviral vector. Hum Gene Ther 2007; 18: 1244\u20131252.","journal-title":"Hum Gene Ther"},{"key":"BFgt201767_CR37","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1038\/mtna.2012.47","volume":"1","author":"PL Sinn","year":"2012","unstructured":"Sinn PL, Cooney AL, Oakland M, Dylla DE, Wallen TJ, Pezzulo AA et al. Lentiviral vector gene transfer to porcine airways. Mol Ther Nucleic Acids 2012; 1: e56.","journal-title":"Mol Ther Nucleic Acids"},{"key":"BFgt201767_CR38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/ng0595-119","volume":"10","author":"L Bi","year":"1995","unstructured":"Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr . Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119\u2013121.","journal-title":"Nat Genet"},{"key":"BFgt201767_CR39","first-page":"612","volume":"34","author":"CK Kasper","year":"1975","unstructured":"Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.","journal-title":"Thromb Diath Haemorrh"},{"key":"BFgt201767_CR40","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/j.1538-7836.2009.03299.x","volume":"7","author":"SL Meeks","year":"2009","unstructured":"Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P . Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model. J Thromb Haemost 2009; 7: 658\u2013664.","journal-title":"J Thromb Haemost"},{"key":"BFgt201767_CR41","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1371\/journal.pbio.0040374","volume":"4","author":"DT Rutkowski","year":"2006","unstructured":"Rutkowski DT, Arnold SM, Miller CN, Wu J, Li J, Gunnison KM et al. Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biol 2006; 4: e374.","journal-title":"PLoS Biol"},{"key":"BFgt201767_CR42","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1074\/jbc.M112.432344","volume":"288","author":"MR Chikka","year":"2013","unstructured":"Chikka MR, McCabe DD, Tyra HM, Rutkowski DT . C\/EBP homologous protein (CHOP) contributes to suppression of metabolic genes during endoplasmic reticulum stress in the liver. J Biol Chem 2013; 288: 4405\u20134415.","journal-title":"J Biol Chem"},{"key":"BFgt201767_CR43","doi-asserted-by":"publisher","first-page":"e20390","DOI":"10.7554\/eLife.20390","volume":"5","author":"JA Gomez","year":"2016","unstructured":"Gomez JA, Rutkowski DT . Experimental reconstitution of chronic ER stress in the liver reveals feedback suppression of BiP mRNA expression. Elife 2016; 5: e20390.","journal-title":"Elife"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/gt201767.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt201767","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/gt.2017.67","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/gt201767.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:30:35Z","timestamp":1648560635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt201767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,14]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["BFgt201767"],"URL":"https:\/\/doi.org\/10.1038\/gt.2017.67","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,14]]},"assertion":[{"value":"24 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CGA, MB and WCR are employees of Virogenics, Inc. Janice Staber has received honorarium from Baxalta.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}